Akero's fatty liver disease drug lessens scarring in mid-stage trial
Adds company comment in paragraph 6, analyst comment in paragraph 10, updates share movement
By Leroy Leo and Puyaan Singh
March 4 (Reuters) -Akero Therapeutics' AKRO.O experimental drug for a type of fatty liver disease significantly reduced scarring after nearly two years in a mid-stage study, it said on Monday, as the company targets a potential multi-billion-dollar market.
The company's shares rose 19% to $33.09 in morning trade and at least one analyst said the drug showed the most benefit in the small study compared with any other treatment tested in separate trials for the disease.
However, the results will have to be confirmed in a late-stage trial.
South San Francisco, California-based Akero was testing the drug, efruxifermin, in a mid-stage trial, that enrolled 128 metabolic dysfunction-associated steatohepatitis (MASH) patients with scarring or fibrosis at severity of stage two or three.
The condition, earlier called non-alcoholic steatohepatitis (NASH), has no approved drugs, with the U.S. Food and Drug Administration expected to decide on rival Madrigal Pharmacauticals' MDGL.O drug by next Thursday.
"I think whoever is approved first has to build that market," Kitty Yale, Akero's chief development officer, said in an interview.
"Then you can take advantage of that ... with drugs that have stronger profiles in terms of overall efficacy," she said.
After 96 weeks, biopsies of 88 patients showed that efruxifermin helped reduce scarring in the liver by at least one stage in 75% of patients who took the higher dose, and in 46% of patients on a lower dose, compared to 24% for placebo.
It helped reduce scarring by at least two stages in over a third of the patients taking a higher dose, and 31% on the lower dose, versus 3% of patients on placebo, Akero said.
The data came above investor expectations, Jefferies analyst Michael Yee said in a note, and forecast $2 billion to $3 billion in peak sales of the drug.
NASH or MASH causes an excessive accumulation of fat in the liver and affects more than 17 million Americans, according to Akero. NeuroBo Pharmaceuticals NRBO.O and 89bio ETNB.O are also developing treatments for the disease.
Reporting by Leroy Leo and Puyaan Singh in Bengaluru; Editing by Shailesh Kuber and Sriraj Kalluvila
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
